Form 4: Assembly Biosciences CEO Jason Okazaki Sells Shares to Cover Tax Obligations, Receives Stock Options

Assembly Biosciences CEO Jason Okazaki sold 354 shares to cover tax obligations related to vested restricted stock units and received 65,000 stock options.

Summary

• On April 1, 2024, Jason Okazaki, CEO and President of Assembly Biosciences, sold 354 shares of common stock at a price of $13.0719 per share to cover tax withholding obligations.
• Following the transaction, Okazaki directly owns 13,826 shares of Assembly Biosciences.
• On March 29, 2024, Okazaki was granted 65,000 stock options with an exercise price of $13.30.
• The stock options vest over four years, with 25% vesting on March 29, 2025, and the remaining 75% vesting in monthly installments until March 29, 2028.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions (share sale for tax obligations and option grant), which are neither particularly positive nor negative.

Positives

• The grant of stock options to the CEO aligns his interests with the long-term performance of the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The sale of shares to cover tax obligations is a common practice.

Stakeholder Impact

• The sale of shares by the CEO could have a minor, temporary impact on the stock price.

Key Dates